These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25311677)

  • 41. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
    Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
    Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Botulinum toxin injection for refractory non-neurogenic overactive bladder. Systematic review].
    Henriet B; Roumeguère T
    Rev Med Brux; 2015; 36(1):29-37. PubMed ID: 25856969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [What to do if pills do not work for urge incontinence--still many questions and ambiguities].
    Koldewijn EL
    Ned Tijdschr Geneeskd; 2012; 156(33):A5099. PubMed ID: 22894810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complications of Botox and their Management.
    Leu R; Stearns GL
    Curr Urol Rep; 2018 Sep; 19(11):90. PubMed ID: 30194497
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pre-operative opening detrusor pressure is predictive of detrusor overactivity following TVT in patients with pre-operative mixed urinary incontinence.
    Panayi DC; Duckett J; Digesu GA; Camarata M; Basu M; Khullar V
    Neurourol Urodyn; 2009; 28(1):82-5. PubMed ID: 19089898
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Understanding clinic options for overactive bladder.
    Bartley JM; Blum ES; Sirls LT; Peters KM
    Curr Urol Rep; 2013 Dec; 14(6):541-8. PubMed ID: 23812967
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Treatment of non-neurogenic masculine urinary incontinence due to overactive bladder: a review by the LUTS committee of the French Urological Association].
    Lebdai S; Haillot O; Azzouzi AR; Benchikh A; Campeggi A; Cornu JN; Delongchamps NB; Dumonceau O; Faix A; Fourmarier M; Lukacs B; Mathieu R; Misrai V; Robert G; de La Taille A; Descazeaud A
    Prog Urol; 2014 Jul; 24(9):588-94. PubMed ID: 24975794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Urodynamic predictors of de novo overactive bladder after single-incision sling.
    Manodoro S; Barba M; Locatelli L; Palmieri S; Marino G; Frigerio M
    Int J Gynaecol Obstet; 2021 Jun; 153(3):412-416. PubMed ID: 33251577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The medical management of urinary incontinence.
    Shaban A; Drake MJ; Hashim H
    Auton Neurosci; 2010 Jan; 152(1-2):4-10. PubMed ID: 19900845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sacral Neuromodulation is Preferred over OnabotulinumtoxinA Injection for Overactive Bladder in Women: Con.
    Bales GT
    J Urol; 2017 Sep; 198(3):500-501. PubMed ID: 28751016
    [No Abstract]   [Full Text] [Related]  

  • 51. Sacral Neuromodulation is Preferred over OnabotulinumtoxinA Injection for Overactive Bladder in Women: Pro.
    Kraus SR
    J Urol; 2017 Sep; 198(3):501-502. PubMed ID: 28751015
    [No Abstract]   [Full Text] [Related]  

  • 52. "Inside-out" transobturator tension-free vaginal tape for management of occult stress urinary incontinence in women undergoing pelvic organ prolapse repair.
    Groutz A; Levin I; Gold R; Pauzner D; Lessing JB; Gordon D
    Urology; 2010 Dec; 76(6):1358-61. PubMed ID: 20974490
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Minimally invasive synthetic suburethral sling operations for stress urinary incontinence in women.
    Ogah J; Cody JD; Rogerson L
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006375. PubMed ID: 19821363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence.
    Gomelsky A; Athanasiou S; Choo MS; Cosson M; Dmochowski RR; Gomes CM; Monga A; Nager CW; Ng R; Rovner ES; Sand P; Tomoe H
    Neurourol Urodyn; 2019 Feb; 38(2):825-837. PubMed ID: 30512219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New surgical approaches for urinary incontinence in women.
    Revicky V; Tincello DG
    Maturitas; 2014 Mar; 77(3):239-42. PubMed ID: 24461934
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What criteria should urologists use when choosing surgery for stress urinary incontinence?
    Scarpero H
    J Urol; 2008 Nov; 180(5):1886-7. PubMed ID: 18801536
    [No Abstract]   [Full Text] [Related]  

  • 57. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.
    Nitti VW; Ginsberg D; Sievert KD; Sussman D; Radomski S; Sand P; De Ridder D; Jenkins B; Magyar A; Chapple C;
    J Urol; 2016 Sep; 196(3):791-800. PubMed ID: 27038769
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overactive Bladder Syndrome, Detrusor Overactivity and the Botulinum Toxin.
    Truzzi JC
    Rev Recent Clin Trials; 2015; 10(2):128-34. PubMed ID: 25880125
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Female slings: where do we stand?
    Bauer RM
    Eur Urol; 2012 Nov; 62(5):852-3; discussion 853-4. PubMed ID: 22633361
    [No Abstract]   [Full Text] [Related]  

  • 60. Evaluating progress on longstanding issues.
    Cox L; Clemens JQ
    Nat Rev Urol; 2014 Feb; 11(2):74-5. PubMed ID: 24418803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.